UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D. C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934.

~~EXCHANGE~~February ~~ACT~~1, OF2008 ~~1934.~~

Date of Report (Date of Earliest Event Reported) ~~December 14, 2007~~


	DNAPrint Genomics, Inc.
	(Exact name of registrant as specified in charter)

Utah

0-31905

59-2780520

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)


	1621 West University Parkway, Sarasota, FL 34243
	(Address of principal executive offices)


	(941) 366-3400
	(Registrant’s Telephone Number, including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~ITEM 28.0501

~~COSTS~~OTHER ~~ASSOCIATED WITH EXIT OR DISPOSAL ACTIVITIES.~~EVENTS

On ~~December~~January 1418, ~~2007~~2008, ~~to reduce its costs,~~ the Registrant ~~closed~~entered ~~the~~into ~~Toronto-based~~a ~~office~~nonbinding letter of ~~its~~intent ~~wholly-owned~~with ~~subsidiary~~Nanobac Pharmaceuticals, ~~Ellipsis~~Incorporated ~~Biotherapeutics Corporation~~ (“~~Ellipsis~~Nanobac”). ~~The~~This ~~Registrant~~letter isof inintent ~~negotiations~~was toamended ~~move the Ellipsis operations to another location in the Toronto area, but if the Registrant is unable to reach a relocation agreement~~ on ~~satisfactory~~February ~~terms and conditions~~1, ~~then the Ellipsis operations will be consolidated with Trace Genetics, Inc~~2008., aThis ~~subsidiary~~letter of ~~the~~intent ~~Registrant~~and ~~located~~amendment inare ~~California. The~~filed ~~Registrant~~with ~~anticipates~~ this ~~will occur during January 2008~~8-K.

~~The~~ITEM ~~Registrant anticipates it will have costs associated with termination benefits of approximately $25,000, moving costs of approximately $50,000 and contract termination costs of approximately $27,000~~9. ~~The estimated total range of amounts expected to be incurred and paid in connection with this closure is approximately $100,000 to $110,000.~~01

~~SIGNATURES~~EXHIBITS

~~Pursuant~~99.01 Non-binding toletter ~~the requirements~~ of ~~the~~intent ~~Securities~~dated ~~Exchange~~January ~~Act of 1934~~18, ~~the~~2008 ~~Registrant~~between ~~has~~Nanobac ~~duly~~Pharmaceuticals, ~~caused~~Incorporated ~~this~~and ~~report to be signed on its behalf by~~ the ~~undersigned, thereunto duly authorized~~Registrant.

~~DNAPrint~~99.02 Amendment ~~Genomics~~dated February 1, ~~Inc.~~2008 ~~By:~~to ~~/s/~~the ~~Richard~~non-binding ~~Gabriel~~letter ~~Richard~~of ~~Gabriel~~intent ~~President~~between Nanobac Pharmaceuticals, Incorporate and the Registrant.

2SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


			DNAPrint Genomics, Inc.


		By:	/s/ Richard Gabriel
			Richard Gabriel
			Chief Executive Officer & President

Filing Compare · DNAPRINT GENOMICS INC